2022-501854-12-00撤回1 期
KISIMA-02 vaccine-based immunotherapy for patients with mutated pancreatic cancer
Amal Therapeutics S.A.4 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2023年6月6日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 15
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Cristina Riccadonna
Scientific
Amal Therapeutics S.A.
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
不适用
Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine ProfilesUveitisNCT07262437University of Milan220
未知
3 期
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung CancerNon-Small Cell Lung CancerjRCT2080220584GlaxoSmithKline K.K.
未知
3 期
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Canceron-Small Cell Lung CancerJPRN-jRCT2080220584GlaxoSmithKline K.K.
进行中（未招募）
1 期
COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2)A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy combined with extensive radiotherapyfor the treatment of stage IV non-small cell lung cancerCTIS2023-510089-28-00Oslo University Hospital HF30
进行中（未招募）
2 期
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerBreast CancerNCT05852691Hoffmann-La Roche83